AbbVie Is a Better Stock Than You Might Think -- Here's Why
AbbVie's (NYSE: ABBV) fortunes have hinged primarily on autoimmune-disease drug Humira for years. That's understandable, considering that Humira has ranked as the world's bestselling drug for nearly a decade.
However, Humira faces biosimilar rivals in the U.S. beginning in 2023. Many investors could be concerned about AbbVie's future as sales for its top blockbuster inevitably decline. But AbbVie is a better stock than you might think.
Image source: Getty Images.
Source Fool.com